Ajanta Pharma Limited Total Assets

Latest as of September 2025: Rs56.72 Billion INR ≈ $613.45 Million USD

Ajanta Pharma Limited total assets. Based on the latest financial reports, Ajanta Pharma Limited (AJANTPHARM) holds total assets worth Rs56.72 Billion INR (≈ $613.45 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Ajanta Pharma Limited (AJANTPHARM) market capitalisation for the company's overall valuation and market capitalisation.

Total Assets of Ajanta Pharma Limited (2005–2025)

Total assets of Ajanta Pharma Limited from 2005 to 2025. This chart illustrates how Ajanta Pharma Limited's total assets have evolved over time, based on quarterly financial data. See current stock price of Ajanta Pharma Limited for real-time trading data and today's change.

Ajanta Pharma Limited - Asset Composition Analysis

Ajanta Pharma Limited Total Assets Breakdown (March 2025)

Ajanta Pharma Limited total assets breakdown as of March 2025. Ajanta Pharma Limited's total assets of Rs56.72 Billion consist of 56.7% current assets and 43.3% non-current assets.

Asset Category Amount (INR) % of Total Assets
Cash & Equivalents Rs0.00 3.5%
Accounts Receivable Rs11.83 Billion 23.6%
Inventory Rs9.04 Billion 18.0%
Property, Plant & Equipment Rs18.92 Billion 37.7%
Intangible Assets Rs465.20 Million 0.9%
Goodwill Rs0.00 0.0%

Asset Composition Trend (2005–2025)

This chart illustrates how Ajanta Pharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore AJANTPHARM net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Ajanta Pharma Limited's current assets represent 56.7% of total assets in 2025, a decrease from 61.1% in 2005.
  • Cash Position: Cash and equivalents constituted 3.5% of total assets in 2025, up from 1.3% in 2005.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 28.0% in 2005.
  • Asset Diversification: The largest asset category is property, plant & equipment at 37.7% of total assets.

Ajanta Pharma Limited Competitors by Total Assets

Key competitors of Ajanta Pharma Limited based on total assets are shown below.

Company Country Total Assets
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
China CN¥9.54 Billion
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
China CN¥6.44 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Renhe Pharmacy Co Ltd
SHE:000650
China CN¥7.93 Billion
Bide Pharmatech Co. Ltd. A
SHG:688073
China CN¥2.54 Billion
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
China CN¥4.69 Billion
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
China CN¥2.26 Billion
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
China CN¥25.73 Billion

Ajanta Pharma Limited - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 2.93 3.07 3.16
Quick Ratio 2.23 2.14 2.15
Cash Ratio 0.00 0.00 0.00
Working Capital Rs22.34 Billion Rs18.86 Billion Rs13.61 Billion

Ajanta Pharma Limited - Advanced Valuation Insights

This section examines the relationship between Ajanta Pharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 8.29
Latest Market Cap to Assets Ratio 0.09
Asset Growth Rate (YoY) 8.1%
Total Assets Rs50.15 Billion
Market Capitalization $4.49 Billion USD

Valuation Analysis

Below Book Valuation: The market values Ajanta Pharma Limited's assets below their book value (0.09x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Ajanta Pharma Limited's assets grew by 8.1% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Ajanta Pharma Limited (2005–2025)

The table below shows the annual total assets of Ajanta Pharma Limited from 2005 to 2025.

Year Total Assets Change
2025-03-31 Rs50.15 Billion
≈ $542.35 Million
+8.12%
2024-03-31 Rs46.38 Billion
≈ $501.62 Million
-0.87%
2023-03-31 Rs46.79 Billion
≈ $506.02 Million
+15.37%
2022-03-31 Rs40.56 Billion
≈ $438.60 Million
+7.33%
2021-03-31 Rs37.79 Billion
≈ $408.65 Million
+13.86%
2020-03-31 Rs33.19 Billion
≈ $358.90 Million
+23.09%
2019-03-31 Rs26.96 Billion
≈ $291.58 Million
+10.11%
2018-03-31 Rs24.49 Billion
≈ $264.81 Million
+34.34%
2017-03-31 Rs18.23 Billion
≈ $197.12 Million
+23.04%
2016-03-31 Rs14.81 Billion
≈ $160.21 Million
+29.23%
2015-03-31 Rs11.46 Billion
≈ $123.97 Million
+20.75%
2014-03-31 Rs9.49 Billion
≈ $102.67 Million
+32.18%
2013-03-31 Rs7.18 Billion
≈ $77.67 Million
+10.70%
2012-03-31 Rs6.49 Billion
≈ $70.17 Million
+24.25%
2011-03-31 Rs5.22 Billion
≈ $56.47 Million
+5.47%
2010-03-31 Rs4.95 Billion
≈ $53.54 Million
+6.96%
2009-03-31 Rs4.63 Billion
≈ $50.06 Million
+28.61%
2008-03-31 Rs3.60 Billion
≈ $38.92 Million
+34.15%
2007-03-31 Rs2.68 Billion
≈ $29.01 Million
+11.41%
2006-03-31 Rs2.41 Billion
≈ $26.04 Million
+11.02%
2005-03-31 Rs2.17 Billion
≈ $23.46 Million
--

About Ajanta Pharma Limited

NSE:AJANTPHARM India Drug Manufacturers - Specialty & Generic
Market Cap
$4.49 Billion
Rs414.75 Billion INR
Market Cap Rank
#3718 Global
#164 in India
Share Price
Rs3319.70
Change (1 day)
-2.26%
52-Week Range
Rs2458.10 - Rs3718.20
All Time High
Rs3718.20
About

Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic a… Read more